1-2 of 2
Justin Lindemann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors

Free
David M. Hyman, Lillian Smyth, Philippe L. Bedard, Amit Oza, Emma Dean, Anne Armstrong, Joao Lima, Hideaki Bando, Peter Kabos, J. Alejandro Perez-Fidalgo, Kathleen Moore, Shannon N. Westin, Benoit You, Sarat Chandarlapaty, Leila Alland, Helen Ambrose, Andrew Foxley, Justin Lindemann, Martin Pass, Paul Rugman, Shaista Salim, Gaia Schiavon, Kenji Tamura, Jose Baselga, Udai Banerji
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B109.
https://doi.org/10.1158/1535-7163.TARG-15-B109
Published: 01 December 2015
View articletitled, Abstract B109: AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors
Journal Articles

Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors

Free
Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D'Cruz, Michael Zinda, Justin Lindemann, Makoto Kodaira, Kenji Tamura, Emma L. Jenkins
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (11): 2441–2451.
https://doi.org/10.1158/1535-7163.MCT-15-0230
Published: 03 November 2015
View articletitled, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Open the PDF for Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors in another window
Includes: Supplementary data